Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 86.13% is in line with its 5-year average of 84.92%, near the high end of its 5-year range (81.88%–86.59%).
0.52% above its 12-month average of 85.69%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 85.48%.
GROSS MARGIN
86.13%
GROSS MARGIN AVG TTM
85.69%
GROSS MARGIN AVG 3Y
85.03%
GROSS MARGIN AVG 5Y
84.92%
GROSS MARGIN AVG 10Y
84.06%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.52%
CURRENT VS 3Y AVG
+1.30%
CURRENT VS 5Y AVG
+1.43%
CURRENT VS 10Y AVG
+2.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.69%
median of 101 covered companies
CURRENT VS SECTOR MEDIAN
+46.75%
vs the sector median at left
Inspire Medical Systems, Inc.
Market Cap
$2.02B
Gross Margin
86.13%
TTM Avg
85.69%
3Y Avg
85.03%
5Y Avg
84.92%
Market Cap
$1.90B
Gross Margin
17.11%
TTM Avg
17.72%
3Y Avg
20.44%
5Y Avg
20.08%
Market Cap
$2.16B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$1.74B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
Market Cap
$1.71B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$2.52B
Gross Margin
84.05%
TTM Avg
-197.31%
3Y Avg
-176.53%
5Y Avg
-71811.06%
Market Cap
$2.76B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$1.00B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$474.59M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. (INSP) | $2.02B | 86.13% | 85.69% | 85.03% | 84.92% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.90B | 17.11% | 17.72% | 20.44% | 20.08% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -61.96% | -19.42% | -14.39% | 23.74% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 49.52% | 50.81% | 52.12% | 52.25% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | 76.47% | 79.35% | 79.86% | 39.87% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | 84.05% | -197.31% | -176.53% | -71811.06% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 58.69% | 59.64% | 63.22% | 64.62% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 73.53% | 70.13% | 70.04% | 68.74% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 42.92% | 41.39% | 40.24% | 40.24% |
| NRC Health (NRC)vs › | $458.62M | 56.33% | 58.27% | 60.30% | 61.48% |
Gross Margin
86.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 85.48% |
| 2026-03-31 | 86.47% |
| 2025-12-31 | 86.59% |
| 2025-09-30 | 85.85% |
| 2025-06-30 | 84.03% |
| 2025-03-31 | 84.75% |
| 2024-12-31 | 84.99% |
| 2024-09-30 | 84.06% |
| 2024-06-30 | 84.77% |
| 2024-03-31 | 84.91% |
| 2023-12-31 | 85.43% |
| 2023-09-30 | 84.10% |
| 2023-06-30 | 83.95% |
| 2023-03-31 | 84.45% |
| 2022-12-31 | 83.94% |
| 2022-09-30 | 81.88% |
| 2022-06-30 | 84.49% |
| 2022-03-31 | 85.58% |
| 2021-12-31 | 85.77% |
| 2021-09-30 | 86.02% |
| 2021-06-30 | 85.80% |
| 2021-03-31 | 85.18% |
| 2020-12-31 | 84.44% |
| 2020-09-30 | 85.46% |
| 2020-06-30 | 83.96% |
| 2020-03-31 | 84.56% |
| 2019-12-31 | 84.25% |
| 2019-09-30 | 83.43% |
| 2019-06-30 | 82.84% |
| 2019-03-31 | 82.44% |
| 2018-12-31 | 80.72% |
| 2018-09-30 | 81.10% |
| 2018-06-30 | 80.78% |
| 2018-03-31 | 77.16% |
| 2017-12-31 | 81.11% |
| 2017-09-30 | 78.48% |
| 2017-06-30 | 77.23% |
| 2017-03-31 | 77.42% |
